TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23002172

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oral Appliances (OAs)
Number of subjects: 121
Study: 21219381

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (EPA and DHA), 1.84 g per day for 32 weeks
Number of subjects: 238
Study: 19633072

Group type: EXPERIMENTAL
Intervention: Patients with MetS
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Patients with MetS with insulin resistance (IR)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control group (subjects without MetS)
Number of subjects: 539
Study: 16719596

Group type: EXPERIMENTAL
Intervention: Female patients with CHD symptoms under stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Female patients with CHD symptoms without stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Male patients with CHD symptoms under stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Male patients with CHD symptoms without stress
Number of subjects: 0
Study: 14985485

Group type: EXPERIMENTAL
Intervention: Infliximab maintenance therapy (5 mg/kg every 8 weeks)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo maintenance
Number of subjects: 306
Study: 11527647

Group type: EXPERIMENTAL
Intervention: Echocardiography with harmonic imaging and contrast injection
Number of subjects: 58

Group type: COMPARATOR
Intervention: Echocardiography without contrast injection
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Echocardiography with contrast injection
Number of subjects: 58
Study: 9481960

Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1000 mg acetaminophen with 10 mg hydrocodone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg ketoprofen
Number of subjects: 30
Study: 8243705

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study: 3105913

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 1.75 mg/kg given over 12 hr (0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Number of subjects: 24
Study: 31077582

Group type: EXPERIMENTAL
Intervention: BT-11 (up to 100 mg/kg, p.o.)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BT-11 (up to 100 mg/kg daily for seven days, orally)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BT-11 (multiple ascending doses)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BT-11 (0.01 µM ex vivo treatment)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30915987

Group type: EXPERIMENTAL
Intervention: PNK (paracetamol, nefopam, ketoprofen)
Number of subjects: 237

Group type: COMPARATOR
Intervention: C (control with saline as placebo)
Number of subjects: 237

Group type: COMPARATOR
Intervention: N (nefopam)
Number of subjects: 237
Study: 28214613

Group type: EXPERIMENTAL
Intervention: Standardized skin care regimens (body wash and twice daily applications of leave-on products for eight weeks)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Routine skin care (control group)
Number of subjects: 133
Study: 25954107

Group type: EXPERIMENTAL
Intervention: Jumbo biopsy forceps (Radial Jaw 4 jumbo)
Number of subjects: 37
Study: 23470803

Group type: EXPERIMENTAL
Intervention: High-dose DRI (300 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination group (standard dose DRI 150 mg + hydrochlorothiazide 12.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard dose DRI (150 mg)
Number of subjects: 30
Study: 20957659

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly for 10 years
Number of subjects: 1272
Study: 19153985

Group type: EXPERIMENTAL
Intervention: Citrus paradisi peel extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citrus paradisi juice
Number of subjects: 0
Study: 17060046

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (continuous infusion of 1.5 mg/kg per hour during operation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no pentoxifylline)
Number of subjects: 30
Study: 13129633

Group type: EXPERIMENTAL
Intervention: 3 months neo-adjuvant maximal androgen deprivation (MAD) with goserelin and flutamide
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: 6 months neo-adjuvant maximal androgen deprivation (MAD) with goserelin and flutamide
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Short-term neo-adjuvant MAD
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Short-term goserelin
Number of subjects: 818

Group type: COMPARATOR
Intervention: All treatment arms (including radiation treatment alone)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Short-term MAD
Number of subjects: 818
Study: 10638985

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist), preoperative administration, dosage and duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2 antagonist), preoperative administration
Number of subjects: 0
Study: 9344321

Group type: EXPERIMENTAL
Intervention: High-dose rTNF alpha + interferon-gamma + melphalan
Number of subjects: 140

Group type: COMPARATOR
Intervention: TNF alpha + melphalan
Number of subjects: 140
Study: 1526756

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (ST)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Long-term dynamic psychotherapy (LT)
Number of subjects: 34
Study: 2863393

Group type: EXPERIMENTAL
Intervention: Intracorporeal injection of 5 mg phentolamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standing upright
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Assuming a supine posture
Number of subjects: 10
Study: 29580959

Group type: EXPERIMENTAL
Intervention: Repetitive tactile stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard stimulation
Number of subjects: 0
Study: 28793884

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical corticosteroid (control group)
Number of subjects: 60
Study: 26523886

Group type: EXPERIMENTAL
Intervention: Body Project
Number of subjects: 66

Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 66
Study: 24055246

Group type: EXPERIMENTAL
Intervention: Spanish UPSA (Sp-UPSA)
Number of subjects: 227
Study: 20803065

Group type: EXPERIMENTAL
Intervention: FEC90 ×6 cycles
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: FEC90 ×4 cycles followed by eight doses of weekly paclitaxel (T)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: FEC90
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Paclitaxel (T)
Number of subjects: 1246
Study: 18226794

Group type: EXPERIMENTAL
Intervention: Ratio production experiment with variable circles
Number of subjects: 10
Study: 17009401

Group type: EXPERIMENTAL
Intervention: S-pantoprazole (20 mg once a day)
Number of subjects: 369

Group type: COMPARATOR
Intervention: racemic pantoprazole (40 mg once a day)
Number of subjects: 369
Study: 15213583

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus multimodal psychosocial treatment (including social skills training)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103
Study: 11257276

Group type: EXPERIMENTAL
Intervention: Current smoking with GSTT1-1 genotype
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: 20+ pack-years with GSTT1-1 genotype
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Current smoking with GSTT1-0 genotype
Number of subjects: 1489

Group type: COMPARATOR
Intervention: 20+ pack-years with GSTT1-0 genotype
Number of subjects: 1489
Study: 9625397

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control diet (American Heart Association prudent diet)
Number of subjects: 605
Study: 7917930

Group type: EXPERIMENTAL
Intervention: 16 g of glutamine per day for 8 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3140688

Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) administered postoperatively in incremental doses up to 1 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) administered postoperatively
Number of subjects: 59
Study: 31834117

Group type: EXPERIMENTAL
Intervention: Early cycled light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late cycled light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed feeding progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical feeding progression
Number of subjects: 0
Study: 30336601

Group type: EXPERIMENTAL
Intervention: Stepping time
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Reallocating time from any behaviour to stepping
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Relocating time from stepping into sleep, sitting, or standing
Number of subjects: 435
Study: 27756395

Group type: EXPERIMENTAL
Intervention: Serological markers (Pf.GLURP.R2, Pf.MSP1.19, CSP, PvAMA1)
Number of subjects: 6502

Group type: EXPERIMENTAL
Intervention: Serological markers
Number of subjects: 6502

Group type: COMPARATOR
Intervention: PCR prevalence and malaria incidence data
Number of subjects: 6502
Study: 24333186

Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24198581

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 20849801

Group type: EXPERIMENTAL
Intervention: Callos calcium phosphate cement (CPC)
Number of subjects: 26
Study: 18838750

Group type: EXPERIMENTAL
Intervention: Oral morphine sulphate 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium diclofenac suppository 100 mg
Number of subjects: 60
Study: 16652054

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) and adherence support (AT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 122
Study: 12958329

Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril (4 mg/d) and diuretic indapamide (as needed)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 10980588

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 500 mg daily for 7 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 1 g daily for a further 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8628544

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 268

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 268
Study: 1611830

Group type: EXPERIMENTAL
Intervention: Insulin Tolerance Test (ITT) with 0.1 U kg‐1 body weight, human Actrapid insulin given as an IV bolus; KITT measured over the period 3-15 min.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Euglycaemic clamp with insulin infusion of 50 mU kg‐1 h‐1 for 120 min; M/I values derived from the clamp.
Number of subjects: 17
Study: 31177595

Group type: EXPERIMENTAL
Intervention: TLL1 AA genotype (329 patients)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: TLL1 AT/TT genotype (123 patients)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Overall cohort (452 patients)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Noncirrhotic patients (348 patients)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Baseline predictors (Male sex, Diabetes, FIB-4 score)
Number of subjects: 452
Study: 29301520

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for 6 weeks
Number of subjects: 59
Study: 26575250

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Sitagliptin 100mg
Number of subjects: 2313
Study: 23789873

Group type: EXPERIMENTAL
Intervention: Mono‐HA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bi‐HA
Number of subjects: 0
Study: 22782041

Group type: COMPARATOR
Intervention: Scaling/root planing only
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Scaling/root planing followed by minocycline placement
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gingival papilla reflection followed by scaling/root planing and flap closure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gingival papilla reflection, scaling/root planing, minocycline placement, and flap closure
Number of subjects: 25
Study: 20729538

Group type: EXPERIMENTAL
Intervention: DHEA (75 mg once a day before and during IVF treatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no DHEA supplementation)
Number of subjects: 33
Study: 18685496

Group type: EXPERIMENTAL
Intervention: VT insertion with adjuvant adenoidectomy
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: VT insertion without adjuvant adenoidectomy
Number of subjects: 541

Group type: COMPARATOR
Intervention: Nonsurgical observation
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Pre- and postintervention Veq difference
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Raw Veq
Number of subjects: 541
Study: 15714184

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (15 microg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 62
Study: 15314402

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 0
Study: 10665626

Group type: EXPERIMENTAL
Intervention: Divalproex oral loading (30 mg/kg/day on days 1 and 2, followed by 20 mg/kg/day on days 3‐10)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Divalproex nonloading (starting dose of 250 mg t.i.d. on days 1 and 2, followed by standard dose titration for days 3 to 10)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lithium carbonate (starting dose of 300 mg t.i.d., followed by standard dose titration for days 3 to 10)
Number of subjects: 59
Study: 8889672

Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (1.2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (4.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buccal buprenorphine (4.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Norbuprenorphine (all routes)
Number of subjects: 6
Study: 2057467

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 989
Study: 3928820

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 181

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 181
Study: 31780034

Group type: EXPERIMENTAL
Intervention: Qing-Xin-Jie-Yu Granule (QXJYG)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 29706008

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 989
Study: 27398953

Group type: EXPERIMENTAL
Intervention: PIB converters (n=20)
Number of subjects: 164

Group type: COMPARATOR
Intervention: PIB-negative individuals (n=123)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: PIB-positive individuals (n=21)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Stable PIB(-) group
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Early symptomatic AD group (n=10)
Number of subjects: 164
Study: 25299437

Group type: EXPERIMENTAL
Intervention: Play fighting
Number of subjects: 210

Group type: COMPARATOR
Intervention: Volleyball (control)
Number of subjects: 210
Study: 22120044

Group type: EXPERIMENTAL
Intervention: 250 mg cocoa flavanols
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 500 mg cocoa flavanols
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low cocoa flavanol (placebo) drink
Number of subjects: 63
Study: 19878615

Group type: EXPERIMENTAL
Intervention: 4-week blueberry and apple juice intervention
Number of subjects: 168
Study: 22751370

Group type: COMPARATOR
Intervention: Nomogram-directed glucose control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nurse-directed glucose control
Number of subjects: 34
Study: 15939621

Group type: EXPERIMENTAL
Intervention: CCECC
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 30
Study: 12883399

Group type: EXPERIMENTAL
Intervention: Midazolam administered extracorporeally (into the circuit)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam administered via central or peripheral access
Number of subjects: 20
Study: 9531857

Group type: EXPERIMENTAL
Intervention: UVB irradiation (8 times over 4 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no UV exposure)
Number of subjects: 34
Study: 7651559

Group type: EXPERIMENTAL
Intervention: Domperidone (3 x 20 mg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ondansetron (3 x 8 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2759694

Group type: EXPERIMENTAL
Intervention: High protein milk (3.1 g/100 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 0
Study: 1195660

Group type: EXPERIMENTAL
Intervention: 99mTc-labelled sulfur colloid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Newly developed vagolytic substance
Number of subjects: 18
Study: 31743193

Group type: EXPERIMENTAL
Intervention: LIA with 2.5 mL/kg of 0.2% ropivacaine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo with 0.9% saline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: LIA with 0.2% ropivacaine
Number of subjects: 152
Study: 28844191

Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the first non-surgical phase (T1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the second surgical phase (T2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multivariable model including four parameters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Detection of Parvimonas micra before therapy
Number of subjects: 80
Study: 25310295

Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DAST
Number of subjects: 113
Study: 24146646

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22303705

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) 200 mL (50 mL SI in 200 mL normal saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (200 mL normal saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 18325114

Group type: EXPERIMENTAL
Intervention: Personalised and supervised exercise programme (PEP) plus manual auricular acupuncture for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Personalised and supervised exercise programme (PEP) alone for 6 weeks
Number of subjects: 80
Study: 16567436

Group type: EXPERIMENTAL
Intervention: Tamoxifen use
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Post-tamoxifen discontinuation
Number of subjects: 99
Study: 12706366

Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) Index and personal ultraviolet radiation (UVR) intensity indicator
Number of subjects: 3200

Group type: COMPARATOR
Intervention: General, written information about sun protection
Number of subjects: 3200
Study: 10912888

Group type: EXPERIMENTAL
Intervention: rhEPO (5,000 U, 3 times weekly for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8826493

Group type: EXPERIMENTAL
Intervention: Paraspinal lumbosacral root blocks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medial branch posterior primary ramus blocks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sciatic nerve blocks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control: lumbar subcutaneous injection of 3 ml of 0.5% bupivacaine
Number of subjects: 33
Study: 1317525

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemophan membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose acetate membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membrane
Number of subjects: 0
Study: 3862341

Group type: EXPERIMENTAL
Intervention: Lateral pterygoid muscle extirpation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control side (intact lateral pterygoid muscle)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Experimental side (lateral pterygoid muscle extirpated)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both sides (control and experimental)
Number of subjects: 21
Study: 30055940

Group type: EXPERIMENTAL
Intervention: PAR1 inhibition (vorapaxar)
Number of subjects: 6177
Study: 27930518

Group type: EXPERIMENTAL
Intervention: Combined therapy of MSC transplantation and butylphthalide
Number of subjects: 42

Group type: COMPARATOR
Intervention: MSC transplantation alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy
Number of subjects: 42
Study: 25051144

Group type: EXPERIMENTAL
Intervention: Triple-deposit method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Single-deposit method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Double-deposit method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Single-deposit or double-deposit groups
Number of subjects: 45
Study: 22343174

Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 0